Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$156.98
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,536,517,632.00
EPSttm : 4.18
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$156.98
2.02%
$3.11

Float Short %

12.66

Margin Of Safety %

30

Put/Call OI Ratio

1.64

EPS Next Q Diff

0.36

EPS Last/This Y

3.11

EPS This/Next Y

3.16

Price

156.98

Target Price

208.27

Analyst Recom

1.17

Performance Q

-5.26

Relative Volume

1.57

Beta

0.7

Ticker: KRYS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04KRYS143.081.25999.9910442
2025-07-07KRYS139.721.279.2110541
2025-07-08KRYS143.341.290.1310661
2025-07-09KRYS149.061.284.6310683
2025-07-10KRYS150.741.280.1010681
2025-07-11KRYS148.251.280.0110703
2025-07-14KRYS150.281.280.0410714
2025-07-15KRYS147.871.251.0410830
2025-07-16KRYS149.971.250.1210898
2025-07-17KRYS1501.250.0710920
2025-07-18KRYS147.521.290.4211107
2025-07-21KRYS148.161.4530.9111736
2025-07-22KRYS151.91.650.3312782
2025-07-23KRYS153.221.640.6012796
2025-07-24KRYS150.541.640.3312788
2025-07-25KRYS147.71.640.1012789
2025-07-28KRYS152.911.631.6412827
2025-07-29KRYS152.111.640.2012960
2025-07-30KRYS153.151.649.5012982
2025-07-31KRYS153.921.650.1913011
2025-08-01KRYS156.921.640.3213025
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04KRYS143.0835.237.35.88
2025-07-07KRYS139.7635.230.35.88
2025-07-08KRYS143.3435.240.05.88
2025-07-09KRYS148.9035.242.65.88
2025-07-10KRYS149.7435.236.15.88
2025-07-11KRYS148.1735.234.05.88
2025-07-14KRYS150.4135.237.95.88
2025-07-15KRYS147.7335.231.45.88
2025-07-16KRYS149.9735.237.95.88
2025-07-17KRYS150.1535.235.05.88
2025-07-18KRYS147.8135.231.95.88
2025-07-21KRYS148.1035.235.75.88
2025-07-22KRYS151.9835.240.15.88
2025-07-23KRYS153.2535.236.75.88
2025-07-24KRYS150.0049.430.86.11
2025-07-25KRYS147.6149.431.86.11
2025-07-28KRYS153.4253.642.66.23
2025-07-29KRYS152.0853.633.86.23
2025-07-30KRYS153.2253.636.46.23
2025-07-31KRYS153.8753.635.76.23
2025-08-01KRYS156.9853.638.86.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04KRYS-2.41-1.3312.23
2025-07-07KRYS-2.41-1.4212.23
2025-07-08KRYS-2.41-1.4212.23
2025-07-09KRYS-2.41-1.4212.23
2025-07-10KRYS-2.41-1.4212.23
2025-07-11KRYS-3.06-1.4212.82
2025-07-14KRYS-3.06-1.3312.82
2025-07-15KRYS-3.06-1.3312.82
2025-07-16KRYS-3.06-1.3312.82
2025-07-17KRYS-4.65-1.3312.83
2025-07-18KRYS-4.65-1.3312.83
2025-07-21KRYS-4.65-1.3612.82
2025-07-22KRYS-4.68-1.3612.82
2025-07-23KRYS-4.68-1.3612.82
2025-07-24KRYS-4.68-1.3612.82
2025-07-25KRYS-4.70-1.3612.66
2025-07-28KRYS-4.70-1.0712.66
2025-07-29KRYS-4.70-1.0712.66
2025-07-30KRYS-4.70-1.0712.66
2025-07-31KRYS-4.70-1.0712.66
2025-08-01KRYS-4.70-1.0712.66
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.26

Avg. EPS Est. Next Quarter

1.56

Insider Transactions

-4.7

Institutional Transactions

-1.07

Beta

0.7

Average Sales Estimate Current Quarter

95

Average Sales Estimate Next Quarter

101

Fair Value

203.69

Quality Score

87

Growth Score

41

Sentiment Score

89

Actual DrawDown %

28.4

Max Drawdown 5-Year %

-53.4

Target Price

208.27

P/E

37.8

Forward P/E

19.37

PEG

0.64

P/S

13.6

P/B

4.61

P/Free Cash Flow

35.08

EPS

4.15

Average EPS Est. Cur. Y​

6.23

EPS Next Y. (Est.)

9.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.18

Relative Volume

1.57

Return on Equity vs Sector %

-11.1

Return on Equity vs Industry %

7.5

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.35

EBIT Estimation

38.8
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading